FLU-IGIV / Emergent Biosolutions - LARVOL DELTA

[VIRTUAL] Anti-influenza immunoglobulin (FLU-IVIG) in hospitalised patients with serious influenza A (ECCMID 2021) - "oseltamivir)... FLU-IGIV was safe and well-tolerated with an apparent dose-dependent PK profile . FLU-IGIV reduced time to hospital discharge and was associated with better outcomes at Day 4 . Further studies are warranted to confirm these data."

Clinical • Infectious Disease • Pain • Respiratory Diseases

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A (clinicaltrials.gov) - P2; N=65; Completed; Sponsor: Emergent BioSolutions; Recruiting ➔ Completed

Clinical • Trial completion